FINWIRES · TerminalLIVE
FINWIRES

Semtech Could See Data Center Revenue Reach $200 Million Quarterly Run-Rate by Fiscal Q1 2028, UBS Says

By

Semtech (SMTC) could see its data center revenue reach a $200 million quarterly run-rate by fiscal Q1 2028, which should offset the revenue impact from the cellular module divestiture, UBS said in a Wednesday note.

The company's fiscal Q3 guidance calls for a 45% quarter-on-quarter growth and a 160% growth over last year in data center revenue, UBS said, adding that it is modeling full-year 2027 data center revenue to grow about 120% year-on-year.

Semtech's sale of the cellular module business is improving the company's gross margin profile by about 500 basis points, according to the note.

The company's fiscal Q3 revenue guidance of $405 million to $415 million was above UBS' pre-earnings call estimate of $376 million. Meanwhile, gross margin expectation was 230 basis points ahead of UBS estimate, resulting in EPS range of $1.02 to $1.08, higher than UBS view of $0.76, the note said.

UBS raised its price target to $230 from $225 and maintained its buy rating.

Price: $137.84, Change: $+10.32, Percent Change: +8.09%

Related Articles

Wire

Update: Worley Fiscal 2026 Underlying EPS, Aggregated Revenue Down; Shares Hit Six-Year Low

(Updates to add stock movement in the headline and the last paragraph.)Worley (ASX:WOR) logged AU$0.782 in underlying earnings per basic share for fiscal 2026, compared with AU$0.902 a year ago, a Wednesday filing showed.Analysts polled by FactSet expected AU$0.77.For the 12 months ended June 30, aggregated revenue was AU$12.02 billion versus AU$12.05 billion previously, the Australia-listed provider of engineering and project delivery services added. Analysts surveyed by FactSet projected AU$11.73 billion.The board proposed a final dividend of AU$0.25 per share, unchanged from a year earlier, payable Sept. 30 to shareholders of record as of Sept. 2.The company guided for fiscal 2027 underlying earnings before interest, taxes, and amortization growth, and for aggregated revenue growth, in the mid-to-high single-digit range.Its shares fell nearly 11% in recent trading on Wednesday and earlier hit their lowest since August 2020.

ASX:WOR
Wire

Update: HEICO Fiscal Q3 Earnings, Revenue Rise

(Updates to add share movement in the fifth paragraph.)HEICO (HEI) reported late Tuesday a fiscal Q3 earnings of $1.67 per diluted share, up from $1.26 a year earlier.Analysts polled by FactSet expected $1.51.Revenue for the quarter ended July 31 was $1.41 billion, up from $1.15 billion a year ago.Analysts expected $1.35 billion.Shares of the company rose 2.5% in after-hours trading.

$HEI
Wire

Spyre Halts Stand-Alone Rheumatoid Arthritis Drug Development; Shares Fall After Hours

Spyre Therapeutics (SYRE) said its experimental rheumatoid arthritis drug SPY072 failed to meet the company's internal performance threshold needed to justify further stand-alone development, prompting the halt of its monotherapy RA program.The drug delivered statistically significant improvements over placebo on several efficacy measures and showed a tolerable safety profile with no drug-related serious adverse events, the company said Tuesday in a statement.Spyre said it will now evaluate SPY072 in combination regimens and in other autoimmune indications, with additional clinical readouts expected in Q4.Spyre shares fell 12% in after-hours trading.

$SYRE